Shilpa Medicare is currently trading at Rs. 550.60, up by 21.65 points or 4.09% from its previous closing of Rs. 528.95 on the BSE.
The scrip opened at Rs. 528.50 and has touched a high and low of Rs. 561.75 and Rs. 528.50 respectively. So far 4913 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 670.95 on 22-Jul-2021 and a 52 week low of Rs. 317.05 on 19-Mar-2021.
Last one week high and low of the scrip stood at Rs. 585.00 and Rs. 527.00 respectively. The current market cap of the company is Rs. 4785.82 crore.
The promoters holding in the company stood at 53.25%, while Institutions and Non-Institutions held 15.18% and 31.57% respectively.
Shilpa Medicare has launched PRUCALSHIL (Prucalopride) Orally Disintegrating Strips 1 mg and 2 mg in India, a unique formulation developed for the first time in the World. The company has developed a novel ‘Orally Disintegrating Strip (ODS)’ formulation for Prucalopride and obtained subsequent approval from Drug Control General of India. Prucalopride is used for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients. Orally Disintegrating Strips have an advantage such as greater dissolution due to large surface area, more patient compliance than oral tablets, no risk of choking & better taste masking etc.
Orally Disintegrating Strips technology is emerging in novel drug delivery formulations. The company has acquired expertise with compliance oriented research for development of novel and safer drug delivery such as oral strips keeping in mind patient convenience.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.65 |
| Dr. Reddys Lab | 1194.55 |
| Cipla | 1465.65 |
| Lupin | 2043.30 |
| Zydus Lifesciences | 944.25 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
